Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + HAIC in liver metastatic colorectal cancer
NCT05511051Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2022
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in colorectal cancer (CRC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05511051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511051.